Only 15 to 20 percent of pancreatic cancer patients qualify for Whipple surgery. The rest have disease that has spread too far or involves blood vessels that make surgery unsafe. Candidacy comes down to three things: where the tumour sits, whether it has grown into major vessels, and whether the patient is fit enough for one of the most demanding operations in oncology.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Whipple surgery is the only operation that offers a realistic chance of cure in pancreatic cancer. But it only works when the cancer is truly resectable, meaning it hasn’t wrapped around the superior mesenteric artery or vein in a way that makes clear margins impossible. The staging assessment before the operation is as important as the operation itself. Getting that wrong in either direction, operating when you shouldn’t or not operating when you should, changes outcomes dramatically.”

Four criteria define resectability. All four need to be met.

• Cancer in the head of the pancreas: The Whipple procedure removes the head of the pancreas, the duodenum, part of the bile duct, the gallbladder and nearby lymph nodes. It’s the right operation for cancers in the pancreatic head. Body and tail cancers need distal pancreatectomy, not Whipple.
• No involvement of major vessels: The superior mesenteric artery and superior mesenteric vein run directly behind the pancreatic head. Cancer that has encased the artery makes clear margins impossible. Abutment alone may still be resectable. Encasement is not.
• No distant metastasis: Liver metastases, peritoneal spread or lung involvement make Whipple palliative at best. Staging CT and PET-CT must confirm disease is localised before the operation is planned.
• Patient fitness: Whipple is a six to eight hour operation with significant physiological demand. Cardiac reserve, lung function, nutritional status and performance score all feed into the fitness assessment. An unfit patient with a resectable tumour may not be a surgical candidate until fitness improves.

For patients whose pancreatic cancer requires minimally invasive surgical removal, robotic cancer surgery includes robotic pancreaticoduodenectomy, available at select high-volume centres with surgeons trained in robotic pancreatic surgery.

Not all unresectable presentations are permanently unresectable.

• Borderline resectable: The tumour abuts but hasn’t encased the superior mesenteric vessels. Surgery is technically possible but margins are at risk. Neoadjuvant chemotherapy, typically FOLFIRINOX or gemcitabine-nab paclitaxel, is given first to shrink the tumour away from the vessels before re-staging.
• Response-guided restaging: After 4 to 6 months of neoadjuvant chemotherapy, CT and sometimes PET-CT reassess whether vessel clearance has improved. Patients who downstage to clearly resectable territory can proceed to Whipple. Not all do.
• Locally advanced but not metastatic: Cancer that has grown significantly into the SMA or coeliac axis. Technically unresectable in most cases. Systemic chemotherapy and sometimes radiation are used. A small proportion downstage enough to revisit surgery.
• Palliative surgery for symptoms: Patients who aren’t Whipple candidates can still have biliary bypass or gastric bypass surgery to relieve jaundice or gastric outlet obstruction without removing the tumour.

For patients with pancreatic cancer where Whipple isn’t possible, our blog on pancreatic cancer survival explains what the outlook looks like across stages and treatment types.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He is among the very few surgeons in India performing robotic Whipple surgery, assesses every pancreatic cancer case at the tumour board before confirming resectability, and coordinates neoadjuvant chemotherapy planning for borderline resectable cases with the medical oncology team.

Whipple surgery is one of the hardest operations to do well. Surgical volume, anatomical familiarity with the pancreatic head and its vascular relationships, and the team behind the surgeon all determine whether a technically demanding resection ends with clear margins and a patient who recovers. That’s the gap between a centre that does this occasionally and one that does it at real volume. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

In oral cancer surgery, neck dissection is part of the same operation in most cases, not a separate procedure. Oral cancers spread to the neck lymph nodes early, often before anything is visible or palpable. Waiting until nodes are clinically positive before clearing them is a risk the evidence doesn’t support. For most tumours at stage T2 and above, and for many T1 tumours with depth of invasion above 4mm, neck dissection happens at the same time as the primary surgery.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Neck dissection with oral cancer surgery is not a question of whether but when and how much. Oral cancers use the lymphatic pathways to the neck before they announce themselves clinically. Waiting for nodes to appear before addressing them is too late in most cases. The decision about which levels to clear and whether both sides need addressing is made at the tumour board, not in the operating room.”

Stage, depth and clinical status all feed into the decision.

• Elective neck dissection: Done when the neck appears clinically clear on examination and imaging but the tumour’s depth of invasion, size or location puts the risk of occult nodal spread above 15 to 20 percent. That threshold is based on the landmark D’Cruz NEJM trial. Levels I to III are cleared as standard.
• Therapeutic neck dissection: Done when nodes are already clinically positive on examination, CT or PET-CT. More extensive. Usually includes levels I to IV, sometimes V depending on which nodes are involved and where.
• Depth of invasion trigger: Tumours with depth of invasion above 4mm carry enough risk of occult nodal spread that elective neck dissection is standard even in early stage oral cancers where the neck appears clear. Depth measured on MRI or post-resection pathology.
• Contralateral neck: Midline tumours, tongue cancers crossing the midline and floor of mouth cancers often spread to both sides of the neck. Bilateral neck dissection is performed in the same operation when staging and tumour location indicate it.

For patients choosing minimally invasive surgery for the neck component of oral cancer treatment, robotic cancer surgery includes the MIND technique, a robotic infraclavicular approach to neck dissection that avoids any visible scar on the neck.

Structured, level-by-level lymph node clearance. Not blind excision.

• Levels cleared: The neck is divided into levels I to V. Oral cancer most commonly spreads to levels I, II and III. These are removed in every elective neck dissection. Levels IV and V are added when clinical findings or frozen section dictates.
• Structures preserved: The spinal accessory nerve controlling shoulder movement, the internal jugular vein and the sternocleidomastoid muscle are preserved unless cancer has directly invaded them. Unnecessary sacrifice causes function loss the patient didn’t need.
• Same operation as primary: Neck dissection happens simultaneously with oral cavity resection in almost every case. Two separate operations and two recoveries when one achieves both is not how experienced surgical oncology teams work.
• Frozen section intraoperatively: Suspicious nodes are sent for frozen section during the operation. Positive findings can prompt extension of the dissection to additional levels before the patient leaves theatre.

For a complete explanation of what neck dissection surgery involves and what recovery looks like, our blog on neck dissection surgery covers the full procedure in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs oral cancer resection with integrated neck dissection, MIND robotic infraclavicular neck dissection for patients wanting no neck scar, and TORS for accessible oropharyngeal tumours, with every case reviewed by the tumour board before the surgical plan is confirmed.

The decision about levels, bilaterality and surgical approach in neck dissection is built on volume. Surgeons who do this every week read the anatomy differently from surgeons who do it occasionally, and that difference shows in recurrence rates and functional outcomes. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Head and neck cancer can recur after robotic surgery, including TORS. The risk depends heavily on the original stage, whether margins were clear, HPV status and whether lymph nodes were involved. HPV-positive oropharyngeal cancers have significantly lower recurrence rates than HPV-negative disease. Most recurrences appear within the first two years. After five years without disease, the risk drops sharply.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Head and neck cancer recurrence after TORS is real, but the numbers are more encouraging than most patients expect, especially for HPV-positive disease. The surveillance schedule isn’t optional, it’s what catches recurrence early enough to treat it. A recurrence found at three months on clinical examination is a very different situation from one found a year later when the patient stopped coming for follow up.”

Stage, margins, biology and nodal status. All four feed into the risk.

• Surgical margin status: Clear margins after TORS significantly reduce local recurrence risk. Close or positive margins raise it. Some patients need adjuvant radiation to the primary site specifically because of margin findings on pathology.
• Lymph node involvement: Positive nodes at surgery mean higher risk of regional and distant recurrence. Neck dissection, performed alongside or after TORS, addresses regional nodes. Positive nodes usually trigger adjuvant radiation or chemoradiation.
• HPV status: HPV-positive oropharyngeal cancer, base of tongue and tonsil, has consistently better outcomes than HPV-negative disease. Three-year recurrence rates for HPV-positive TORS patients in published series sit below 15 percent. HPV-negative disease is more aggressive and recurs more often.
• Stage at surgery: Stage I and II disease treated with TORS alone has low recurrence rates. Stage III and IV disease with nodal involvement needs adjuvant treatment and carries a higher long-term recurrence risk even when surgery is successful.

For patients whose recurrence workup or salvage plan involves further minimally invasive surgery, robotic cancer surgery remains an option for selected recurrences in anatomically accessible sites.

Structured surveillance. Not passive monitoring.

• Clinical examination schedule: Every 6 to 8 weeks in the first year, every 3 months in year two, then less frequently. The surgeon examines the primary site, neck and oral cavity at every visit. This is when most recurrences are found first.
• Nasendoscopy: Flexible scope examination of the primary site including base of tongue, tonsil, pharynx and larynx. Allows direct visualisation of areas not visible on external examination. Done at each follow up.
• PET-CT imaging: At 3 to 6 months post-treatment to confirm complete response. Repeated if symptoms develop or examination raises concern. The most sensitive tool for detecting occult regional or distant recurrence.
• Salvage options: Local recurrence after TORS can sometimes be re-resected robotically. Regional neck recurrence may be salvage dissected. Distant metastases are managed with systemic treatment. Early detection is what keeps salvage surgery on the table.

For patients wanting to understand what TORS involves and what the procedure itself achieves, our blog on TORS surgery covers the full picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs TORS for oropharyngeal and base of tongue cancers, MIND neck dissection, and RABIT thyroid surgery, integrating recurrence surveillance into the post-surgical plan from the first consultation so patients understand the follow up commitment before they leave theatre.

High-volume TORS surgery means the margin decisions, neck dissection planning and adjuvant therapy discussions happen with a surgeon who reads this anatomy every week, not occasionally. That familiarity is what separates a good outcome from a preventable recurrence. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Most cancer pain is chronic and managed with medication. But some pain in cancer patients signals something acute and structural. Obstruction, perforation, bleeding, spinal cord compression. These aren’t pain management problems. They’re surgical problems. And the window between symptom onset and irreversible damage can be hours, not days.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Cancer patients and families sometimes wait too long with sudden severe pain because they assume it’s part of the disease. Sometimes it is. But sometimes it’s a perforation or a cord compression that needs an operating theatre or emergency imaging within hours. The rule I give families is simple. If the pain is sudden, severe and different from what’s been there before, go to a surgeon the same day. Don’t manage it at home.”

Four situations change cancer pain from chronic to urgent.

• Bowel obstruction: Crampy, colicky, worsening abdominal pain with bloating, no bowel movements and vomiting. Colon, ovarian and peritoneal cancers are common causes. If the bowel perforates, it becomes a life-threatening emergency within hours. Go to hospital, not a GP.
• Perforation: Sudden onset, severe abdominal pain, rigid abdomen, fever. A tumour has eroded through the bowel wall or stomach. Air under the diaphragm on X-ray confirms it. Needs emergency surgery. Minutes matter here.
• Haemorrhage: Sudden severe pain in the abdomen or flank alongside dropping blood pressure, rapid pulse or visible blood in stool or urine. Tumour bleeding can be catastrophic. Stable patients may be embolised. Unstable ones need the operating theatre.
• Spinal cord compression: Sudden severe back pain with progressive leg weakness, numbness or loss of bladder or bowel control. Bone metastases compressing the spinal cord. Same-day MRI and often emergency surgery or radiation within 24 hours. Every hour of delay reduces the chance of neurological recovery.

For cancer patients who reach emergency surgery, robotic cancer surgery is available for appropriate elective cases but true surgical emergencies are managed with whatever approach gets the patient safe fastest.

The distinction is in the character of the pain, not just the intensity.

• Sudden onset vs gradual: Chronic cancer pain builds over days or weeks. Surgical emergency pain often strikes sharply within minutes. A patient who was comfortable two hours ago and is now writhing needs urgent assessment, not a dose increase.
• New location or new character: Pain in a familiar site that suddenly shifts character, from dull ache to sharp cramp or constant burning, suggests something structural has changed. Obstruction, bleeding and perforation all change the pain character before the clinical signs appear.
• Associated features: Fever with abdominal pain. Leg weakness with back pain. Absence of bowel sounds with distension. These combinations move the assessment from pain management into emergency surgery territory immediately.
• Failure to respond to opioids: Visceral pain from obstruction or perforation often doesn’t respond to typical opioid doses the way chronic cancer pain does. A patient taking regular morphine who reports no relief from additional doses has a warning sign that something acute is happening.

For patients and families wanting to understand how cancer surgery decisions are made generally, our blog on cancer surgery explains the full clinical picture including when urgency applies.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He manages surgical emergencies in cancer patients including bowel obstruction, perforation, haemorrhage and post-operative complications, working with the emergency and ICU teams at KIMS Hospital to stabilise and operate when the clinical picture demands it.

What makes surgical emergencies in cancer patients different from standard emergencies is the background disease. Getting it right requires a surgeon who understands both the oncological context and the acute presentation, not just one or the other. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

The appendix sits next to the colon, but cancer arising there is a different disease entirely. Different cell types, different spread pattern, different staging system, different treatment. Most appendix cancers are slow-growing mucin-producing tumours. Colon cancer is overwhelmingly adenocarcinoma. Treating one like the other is a clinical mistake with real consequences.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients come in having been told it’s just colon cancer in the appendix. It isn’t. The biology is different, the staging is different, and the treatment is completely different. Appendix cancer with peritoneal spread needs cytoreductive surgery and HIPEC, not standard colorectal chemotherapy. Getting that distinction right at the start is the difference between a potentially curative operation and the wrong treatment entirely.”

Four things set them apart. At every level.

• Different tumour types: Most appendix cancers are low-grade mucinous neoplasms, goblet cell carcinoids or well-differentiated neuroendocrine tumours. Colon cancer is almost always adenocarcinoma from the colonic lining. Different cell origin. Different biological behaviour. Different prognosis.
• Different spread pattern: Colon cancer travels through lymphatics and blood to reach the liver and lungs. Appendix cancer, when it ruptures, seeds mucin directly across the peritoneal surfaces. That’s pseudomyxoma peritonei. It coats the abdomen rather than travelling to distant organs via the bloodstream.
• Different staging approach: Colon cancer uses TNM staging based on depth of invasion and nodal spread. Appendix cancer with peritoneal involvement uses the Peritoneal Cancer Index to measure the extent of abdominal surface disease. Entirely different system, entirely different criteria for what’s resectable.
• Different systemic chemotherapy response: FOLFOX and FOLFIRI, standard colorectal regimens, have very limited activity in low-grade appendiceal mucinous tumours. The biology doesn’t respond the same way. Applying colon cancer chemotherapy to appendix cancer produces poor results because the target is wrong.

For patients whose appendix cancer requires surgical removal as part of their treatment plan, robotic cancer surgery provides minimally invasive right hemicolectomy with precision and faster recovery than open approaches.

The treatment is specific to how this cancer spreads. Not interchangeable with colon cancer.

• Right hemicolectomy for localised disease: Cancer confined to the appendix without peritoneal seeding. Remove the appendix and the right colon together. No HIPEC needed at this stage. Surveillance follows.
• CRS and HIPEC for peritoneal spread: When appendix cancer has seeded the peritoneal surfaces, cytoreductive surgery removes all visible disease across the abdomen. Heated intraperitoneal chemotherapy follows immediately in the same operation. Not palliative. For selected patients it’s potentially curative.
• Pseudomyxoma peritonei: A ruptured appendix tumour has released mucin throughout the abdomen. Managed with CRS and HIPEC at experienced centres. Five-year survival above 50 percent in published series. Not a death sentence if the right team is involved.
• Watch and wait for very early LAMN: Low-grade appendiceal mucinous neoplasm, no rupture, no peritoneal involvement, confined to the appendix wall. Appendicectomy alone may be sufficient. Close surveillance required afterwards.

For patients who want to understand what HIPEC involves and what survival outcomes look like for appendix cancer specifically, our blog on HIPEC surgery covers it in detail.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs CRS and HIPEC for appendix cancer with peritoneal spread, right hemicolectomy for localised disease, and presents every appendix cancer case to the tumour board so the plan reflects the actual biology of the tumour, not a default colon cancer protocol.

The difference between being treated as a colon cancer patient and being treated as an appendix cancer patient with peritoneal disease is the difference between the wrong chemotherapy and a potentially curative operation. That distinction is what MACS Clinic exists to make. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.